All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Eprenetapopt receives FDA Fast Track designation for the treatment of AML
On November 30, 2020, it was announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to eprenetapopt/APR-246 for the treatment of patients with TP53-mutated acute myeloid leukemia (AML).1
Eprenetapopt is a small molecule that reactivates mutant and inactivated p53 protein to induce apoptosis in cancer cells. It has previously received FDA Breakthrough Therapy designation, orphan drug designation, and Fast Track designation for the treatment of myelodysplastic syndromes (MDS), as well as orphan drug designation from the European Medicines Agency (EMA) for MDS, AML, and ovarian cancer.
The emerging clinical data are encouraging, as shown by the safety and efficacy results presented at this year’s European Hematology Association (EHA) Annual Congress, and clinical trials evaluating combination therapies with azacitidine or azacitidine plus venetoclax are continuing to expand to identify the best treatment regimen.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content